Quality Failures at Generic Drug Maker Put Patients at Risk, FDA Warns
Manufacturing problems at Akorn Inc.’s New Jersey plant “pose a risk to patients,” U.S. regulators have warned the embattled generic-drug maker, which blew a $4.3 billion takeover deal with Fresenius SE two years ago over similar allegations. In a warning …